This webinar describes the optimization and validation of two commercially available clinical research next-generation sequencing (NGS) assays. The first assay is aimed at identifying fusion transcripts and can identify novel fusion partners. The second assay is used to detect pharmacogenomic targets in cancers that have not responded to current standard treatment. This webinar focuses on sarcoma samples, but the approaches used are applicable to different cancer types including other solid tumors and hematological malignancies.

View related videos
Next generation sequencing-based analyses of hematological malignancies [ Ссылка ]

View related information
TruSight RNA Fusion Panel
[ Ссылка ]

Cancer Cytogenetics Solutions
[ Ссылка ]

Introduction to Cytogenomics
[ Ссылка ]

Subscribe to the Illumina video channel
[ Ссылка ]


For Research Use Only. Not for use in diagnostic procedures.

свернуть